CYTOO specializes in advanced cell-based assays and imaging technologies that enhance drug discovery and development processes. Their innovative platform focuses on the use of engineered cell lines and high-content screening to provide detailed insights into cellular responses. By utilizing a combination of proprietary cell culture techniques and sophisticated imaging systems, CYTOO enables researchers to assess the effects of compounds on cellular behavior with high precision and reproducibility.

The company’s technology is designed to facilitate the analysis of complex biological systems, allowing for the evaluation of various parameters such as cell morphology, viability, and function. This approach not only accelerates the identification of potential drug candidates but also improves the understanding of disease mechanisms. CYTOO's commitment to integrating cutting-edge science with practical applications positions it as a leader in the field of cell-based research, ultimately contributing to more effective therapeutic solutions.

France

CYTOO is a preclinical stage drug discovery company specialized in muscular and neuromuscular disorders. CYTOO partners its versatile patient-derived muscle drug discovery engine to pharma and biotech companies and develops its own drug candidates.
CYOO has developed a fully mature human in vitro muscle model (MyoScreen) derived from primary human samples (healthy and pathological myoblasts) for generating NCEs from a variety of pathological conditions (rare, chronic). Core expertise lies on in vitro muscle regeneration, contraction, hypertrophy, and metabolism.

7 parvis louis néel, grenoble, auvergne-rhône-alpes, france

CYTOO

Company Details